Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.
Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.
复制标题
DOI：
10.1021/acsnano.0c03109
复制
发表时间：
2020-09-22
期刊：
影响因子：
17.1
通讯作者：
Hammond PT
中科院分区：
文献类型：
--
作者：
Barberio AE;Smith SG;Correa S;Nguyen C;Nhan B;Melo M;Tokatlian T;Suh H;Irvine DJ;Hammond PT
尽管细胞因子疗法是在肿瘤中建立更稳健的免疫应答的有吸引力的策略，但细胞因子由于毒性而面临临床失败。特别是，白细胞介素-12已显示出巨大的临床前景，但由于全身毒性而限制了翻译。在这项研究中，我们证明了在不影响IL-12治疗疗效的情况下降低毒性的能力增强。我们设计NP的材料特性，以满足通过使用逐层（LbL）方法对最佳细胞因子递送的增强需求。重要的是，使用LbL，我们证明了NPs的细胞水平运输优先定位于细胞的外表面，并作为药物仓库，这是相邻细胞因子膜受体上的最佳有效载荷活性所需的。LbL-NP在结肠直肠和卵巢肿瘤中显示出对抗肿瘤攻击的功效，其剂量在无载体施用时是不耐受的。
Although cytokine therapy is an attractive strategy to build a more robust immune response in tumors, cytokines have faced clinical failures due to toxicity. In particular, interleukin-12 has shown great clinical promise but was limited in translation due to systemic toxicity. In this study, we demonstrate an enhanced ability to reduce toxicity without affecting efficacy of IL-12 therapy. We engineer the material properties of a NP to meet the enhanced demands for optimal cytokine delivery by using the layer-by-layer (LbL) approach. Importantly, using LbL, we demonstrate cell-level trafficking of NPs to preferentially localize to the cell’s outer surface and act as a drug depot, which is required for optimal payload activity on neighboring cytokine membrane receptors. LbL-NPs showed efficacy against a tumor challenge in both colorectal and ovarian tumors at doses that were not tolerated when administered carrier-free.
登录
查看更多内容
影响因子：
7.4
作者：
Galon J;Pagès F;Marincola FM;Angell HK;Thurin M;Lugli A;Zlobec I;Berger A;Bifulco C;Botti G;Tatangelo F;Britten CM;Kreiter S;Chouchane L;Delrio P;Arndt H;Asslaber M;Maio M;Masucci GV;Mihm M;Vidal-Vanaclocha F;Allison JP;Gnjatic S;Hakansson L;Huber C;Singh-Jasuja H;Ottensmeier C;Zwierzina H;Laghi L;Grizzi F;Ohashi PS;Shaw PA;Clarke BA;Wouters BG;Kawakami Y;Hazama S;Okuno K;Wang E;O'Donnell-Tormey J;Lagorce C;Pawelec G;Nishimura MI;Hawkins R;Lapointe R;Lundqvist A;Khleif SN;Ogino S;Gibbs P;Waring P;Sato N;Torigoe T;Itoh K;Patel PS;Shukla SN;Palmqvist R;Nagtegaal ID;Wang Y;D'Arrigo C;Kopetz S;Sinicrope FA;Trinchieri G;Gajewski TF;Ascierto PA;Fox BA
通讯作者：
Fox BA
用于全身性抗癌药物和siRNA的全层纳米颗粒，用于潜在的三阴性乳腺癌治疗。
影响因子：
17.1
作者：
Deng, Zhou J.;Morton, Stephen W.;Ben-Akiva, Elana;Dreaden, Erik C.;Shopsowitz, Kevin E.;Hammond, Paula T.
通讯作者：
Hammond, Paula T.
影响因子：
8.8
作者：
Abiko, K.;Matsumura, N.;Hamanishi, J.;Horikawa, N.;Murakami, R.;Yamaguchi, K.;Yoshioka, Y.;Baba, T.;Konishi, I.;Mandai, M.
通讯作者：
Mandai, M.
DOI：
10.1158/1078-0432.ccr-15-0013
发表时间：
2015-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Dreaden EC;Kong YW;Morton SW;Correa S;Choi KY;Shopsowitz KE;Renggli K;Drapkin R;Yaffe MB;Hammond PT
通讯作者：
Hammond PT
DOI：
10.1016/j.jconrel.2013.10.016
发表时间：
2013-12-28
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Ganesh S;Iyer AK;Gattacceca F;Morrissey DV;Amiji MM
通讯作者：
Amiji MM